Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities Christensen JGAnn Oncol 2007[Sep]; 18 Suppl 10 (ä): x3-10Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both angiogenic pathways (i.e., vascular endothelial growth factor receptor and platelet-derived growth factor receptor) and direct pro-oncogenic pathways (e.g., stem-cell factor receptor and FMS-like tyrosine kinase-3). Preclinical studies with this agent have indicated that it exhibits robust inhibitory activity against these targets. Clinical trial results have demonstrated the therapeutic potential of this agent and have implicated sunitinib targets in the pathophysiology of malignancies such as renal cell carcinoma and gastrointestinal stromal tumour. This paper reviews the preclinical data supporting the development of this agent and its translation from benchtop to bedside. It also highlights the importance of the multiple pathways that may be involved in cancer progression and the importance of these pathways in selected malignancies.|Angiogenesis Inhibitors/*pharmacology[MESH]|Animals[MESH]|Antineoplastic Agents/*pharmacology[MESH]|Humans[MESH]|Indoles/*pharmacology[MESH]|Neoplasms/*drug therapy/*enzymology/pathology[MESH]|Neovascularization, Pathologic/drug therapy/enzymology[MESH]|Protein Kinase Inhibitors/*pharmacology[MESH]|Pyrroles/*pharmacology[MESH]|Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/metabolism[MESH]|Sunitinib[MESH] |
